ChemBridge and CRL to collaborate with AstraZeneca

24 September 2006

San Diego, USA-based ChemBridge, a specialist contract research organization, and ChemBridge Research Laboratories, a provider of chemistry solutions for use in drug discovery, say they have signed a multi-year collaboration with Anglo-Swedish drug giant AstraZeneca.

Under the terms of the accord, researchers at sites in Moscow, Russia, and San Diego will work closely with AstraZeneca on the development of small-molecule libraries, designed to enhance the latter's global drug discovery effort. Financial terms of the deal were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight